BMJ  2008;336:580-581 (15 March), doi:10.1136/bmj.39513.541296.DB

News

94% of patients suing Merck over rofecoxib agree to company’s offer

¹ Florida

The first 150 words of the full text of this article appear below.

A large enough proportion of the litigants suing Merck after taking the drug rofecoxib (Vioxx) have agreed to the terms of the company’s offer to allow the settlement to go ahead.

Eighty five per cent of claimants had to agree to the settlement to proceed, and by the beginning of this month 94% (44 000 of the 47 000) had done so. The company announced in November a settlement worth $4.85bn (£2.41bn; 3.15bn).

The individual awards, estimated at $150 000 to $200 000 on average, will be calculated in a three step process to assess the severity of injuries. Plaintiffs must provide evidence of a heart attack or ischaemic stroke; proof that they received at least 30 rofecoxib pills; and evidence that they took at least one of the pills within 14 days of injury.

Merck withdrew rofecoxib, which averaged $2.5bn in annual sales, in September 2004 (BMJ 2004;329:816; . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Merck to pay $58m in settlement over rofecoxib advertising

Fred Charatan
BMJ 2008 336: 1208-1209. [Extract] [Full Text] [PDF]

US confirms federal authority for safety of medical devices

Fred Charatan
BMJ 2008 336: 470. [Extract] [Full Text] [PDF]

Merck to pay $5bn in rofecoxib claims

Fred Charatan
BMJ 2007 335: 1011. [Extract] [Full Text] [PDF]

Merck faces ongoing claims after Texan ruling on rofecoxib

Janice Hopkins Tanne
BMJ 2005 331: 471. [Extract] [Full Text] [PDF]

Merck withdraws arthritis drug worldwide

Debashis Singh
BMJ 2004 329: 816. [Extract] [Full Text] [PDF]

Online poll

Find out more here>> and here>>